These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32708181)

  • 1. Sphingolipid Analysis Indicate Lactosylceramide as a Potential Biomarker of Inflammatory Bowel Disease in Children.
    Filimoniuk A; Blachnio-Zabielska A; Imierska M; Lebensztejn DM; Daniluk U
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Sphingolipids in Pediatric Patients with Cholelithiasis-A Preliminary Study.
    Zdanowicz K; Bobrus-Chcociej A; Pogodzinska K; Blachnio-Zabielska A; Zelazowska-Rutkowska B; Lebensztejn DM; Daniluk U
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value.
    Olives JP; Breton A; Hugot JP; Oksman F; Johannet C; Ghisolfi J; Navarro J; Cézard JP
    J Pediatr Gastroenterol Nutr; 1997 Aug; 25(2):142-8. PubMed ID: 9252899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease.
    van Gaal N; Lakenman R; Covington J; Savage R; de Groot E; Bomers M; Benninga M; Mulder C; de Boer N; de Meij T
    J Breath Res; 2017 Nov; 12(1):016006. PubMed ID: 28439048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases.
    Heydari R; Fayazzadeh S; Shahrokh S; Shekari F; Farsad F; Meyfour A
    Inflamm Bowel Dis; 2024 May; 30(5):795-807. PubMed ID: 37855715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis.
    Mortensen JH; Godskesen LE; Jensen MD; Van Haaften WT; Klinge LG; Olinga P; Dijkstra G; Kjeldsen J; Karsdal MA; Bay-Jensen AC; Krag A
    J Crohns Colitis; 2015 Oct; 9(10):863-72. PubMed ID: 26188349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn's Disease and Ulcerative Colitis-A Preliminary Study.
    Daniluk U; Daniluk J; Kucharski R; Kowalczyk T; Pietrowska K; Samczuk P; Filimoniuk A; Kretowski A; Lebensztejn D; Ciborowski M
    Inflamm Bowel Dis; 2019 Jun; 25(7):1120-1128. PubMed ID: 30772902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
    Ciećko-Michalska I; Fedak D; Mach T
    Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease.
    Hisamatsu T; Okamoto S; Hashimoto M; Muramatsu T; Andou A; Uo M; Kitazume MT; Matsuoka K; Yajima T; Inoue N; Kanai T; Ogata H; Iwao Y; Yamakado M; Sakai R; Ono N; Ando T; Suzuki M; Hibi T
    PLoS One; 2012; 7(1):e31131. PubMed ID: 22303484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.
    Tonkic A; Kumric M; Akrapovic Olic I; Rusic D; Zivkovic PM; Supe Domic D; Sundov Z; Males I; Bozic J
    World J Gastroenterol; 2024 Apr; 30(13):1899-1910. PubMed ID: 38659482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study.
    Haak W; Jagt JZ; de Meij TGJ; Bikker FJ; Brand HS; de Boer NKH; Kaman WE
    FASEB J; 2024 May; 38(9):e23627. PubMed ID: 38690708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases.
    Korkmaz H; Asıl M; Temel T; Öztürk B; Kebapçılar L
    Turk J Med Sci; 2021 Oct; 51(5):2403-2412. PubMed ID: 33984894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum galectins as potential biomarkers of inflammatory bowel diseases.
    Yu TB; Dodd S; Yu LG; Subramanian S
    PLoS One; 2020; 15(1):e0227306. PubMed ID: 31929564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.
    Dawiskiba T; Deja S; Mulak A; Ząbek A; Jawień E; Pawełka D; Banasik M; Mastalerz-Migas A; Balcerzak W; Kaliszewski K; Skóra J; Barć P; Korta K; Pormańczuk K; Szyber P; Litarski A; Młynarz P
    World J Gastroenterol; 2014 Jan; 20(1):163-74. PubMed ID: 24415869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum immunoinflammation-related protein complexes discriminate between inflammatory bowel disease and colorectal cancer.
    Sun YH; Li J; Shu HJ; Li ZL; Qian JM
    Clin Transl Oncol; 2019 Dec; 21(12):1680-1686. PubMed ID: 30955196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
    Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
    PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci.
    Drobin K; Assadi G; Hong MG; Andersson E; Fredolini C; Forsström B; Reznichenko A; Akhter T; Ek WE; Bonfiglio F; Hansen MB; Sandberg K; Greco D; Repsilber D; Schwenk JM; D'Amato M; Halfvarson J
    Inflamm Bowel Dis; 2019 Jan; 25(2):306-316. PubMed ID: 30358838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
    Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
    Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
    Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory values in Japanese children with newly diagnosed inflammatory bowel disease.
    Takaki Y; Mizuochi T; Eda K; Ishihara J; Yamashita Y
    Pediatr Int; 2019 Jul; 61(7):720-725. PubMed ID: 31102555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.